Literature DB >> 25204668

Secular trends in the incidence of cholangiocarcinoma in the USA and the impact of misclassification.

Gia L Tyson1, Jawad A Ilyas, Zhigang Duan, Linda K Green, Mamoun Younes, Hashem B El-Serag, Jessica A Davila.   

Abstract

BACKGROUND AND AIMS: It has been reported that the incidence of intrahepatic cholangiocarcinoma (ICC) has increased in the USA, while extrahepatic cholangiocarcinoma (ECC) has decreased or remained stable. However, neither the recent trends nor the effects of the misclassification of Klatskin tumors are known.
METHODS: Using the Surveillance, Epidemiology, and End Results program databases, we calculated the average annual age-adjusted incidence rates (AA-IRs) of ICC and ECC in 4-year time periods (1992-1995, 1996-1999, 2000-2003, 2004-2007). These AA-IRs were calculated with misclassified as well as correctly classified Klatskin tumors. AA-IRs were also calculated based on age, sex, and race. Multivariable Poisson regression models were used to evaluate the secular trends of ICC and ECC.
RESULTS: The AA-IR of ICC was 0.92 in 1992-1995 and 0.93 in 2004-2007, while the AA-IR of ECC increased from 0.70 in 1992-1995 to 0.95 in 2004-2007. There was no significant trend in AA-IR of ICC (p = 0.07), while there was a significant increase in ECC across the 4-year time periods (p < 0.001). Klatskin tumors comprised 6.7% of CCs with approximately 90 and 45% misclassified as ICC during 1992-2000 and 2001-2007, respectively. Adjusted Poisson models showed no significant differences in the temporal trend of ICC or ECC due to misclassification of Klatskin tumors.
CONCLUSIONS: The incidence of ICC has remained stable between 1992 and 2007 with only slight fluctuations, while the incidence of ECC has been increasing. Misclassification of Klatskin tumors does not appear to play a significant role in the trends of CCs.

Entities:  

Mesh:

Year:  2014        PMID: 25204668      PMCID: PMC4823008          DOI: 10.1007/s10620-014-3276-2

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

Review 2.  Cholangiocarcinoma.

Authors:  Tushar Patel
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2006-01

Review 3.  Risk factors for cholangiocarcinoma.

Authors:  Gia L Tyson; Hashem B El-Serag
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

Review 4.  Cholangiocarcinoma: update and future perspectives.

Authors:  Manuela Gatto; Maria Consiglia Bragazzi; Rossella Semeraro; Cristina Napoli; Raffaele Gentile; Alessia Torrice; Eugenio Gaudio; Domenico Alvaro
Journal:  Dig Liver Dis       Date:  2010-01-22       Impact factor: 4.088

5.  Changing international trends in mortality rates for liver, biliary and pancreatic tumours.

Authors:  Shahid A Khan; Simon D Taylor-Robinson; Mireille B Toledano; Angus Beck; Paul Elliott; Howard C Thomas
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

6.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

7.  Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma.

Authors:  S A Khan; M B Toledano; S D Taylor-Robinson
Journal:  HPB (Oxford)       Date:  2008       Impact factor: 3.647

8.  Liver, gallbladder, extrahepatic bile ducts, and pancreas.

Authors:  M T Carriaga; D E Henson
Journal:  Cancer       Date:  1995-01-01       Impact factor: 6.860

9.  Rising trends in cholangiocarcinoma: is the ICD classification system misleading us?

Authors:  Shahid A Khan; Shireen Emadossadaty; Nimzing G Ladep; Howard C Thomas; Paul Elliott; Simon D Taylor-Robinson; Mireille B Toledano
Journal:  J Hepatol       Date:  2011-12-13       Impact factor: 25.083

10.  Worldwide trends in mortality from biliary tract malignancies.

Authors:  Tushar Patel
Journal:  BMC Cancer       Date:  2002-05-03       Impact factor: 4.430

View more
  35 in total

Review 1.  Current biologics for treatment of biliary tract cancers.

Authors:  Diana Y Zhao; Kian-Huat Lim
Journal:  J Gastrointest Oncol       Date:  2017-06

2.  Biliary tract cancer incidence and trends in the United States by demographic group, 1999-2013.

Authors:  Alison L Van Dyke; Meredith S Shiels; Gieira S Jones; Ruth M Pfeiffer; Jessica L Petrick; Jennifer L Beebe-Dimmer; Jill Koshiol
Journal:  Cancer       Date:  2019-01-15       Impact factor: 6.860

3.  Trends in liver cancer mortality in the United States: Dual burden among foreign- and US-born persons.

Authors:  Meheret Endeshaw; Benjamin D Hallowell; Hilda Razzaghi; Virginia Senkomago; Matthew T McKenna; Mona Saraiya
Journal:  Cancer       Date:  2018-11-27       Impact factor: 6.860

Review 4.  Genomic Profiling of Biliary Tract Cancers and Implications for Clinical Practice.

Authors:  Apurva Jain; Lawrence N Kwong; Milind Javle
Journal:  Curr Treat Options Oncol       Date:  2016-11

5.  Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014.

Authors:  Eke Ransome; Li Tong; Jairo Espinosa; Jesse Chou; Vishal Somnay; Gitonga Munene
Journal:  J Gastrointest Oncol       Date:  2019-04

6.  Rising trends in intrahepatic cholangiocarcinoma incidence and mortality: getting at the root cause.

Authors:  Mustafa Raoof; Gagandeep Singh
Journal:  Hepatobiliary Surg Nutr       Date:  2019-06       Impact factor: 7.293

7.  Increasing mortality of intrahepatic cholangiocarcinoma in the US: are gender-specific risk factors important?

Authors:  Samuel O Antwi; Tushar Patel
Journal:  Hepatobiliary Surg Nutr       Date:  2019-12       Impact factor: 7.293

8.  Cohort contributions to trends in the incidence and mortality of intrahepatic cholangiocarcinoma.

Authors:  Eliza W Beal; Dmitry Tumin; Dimitrios Moris; Xu-Feng Zhang; Jeffery Chakedis; Mary Dilhoff; Carl M Schmidt; Timothy M Pawlik
Journal:  Hepatobiliary Surg Nutr       Date:  2018-08       Impact factor: 7.293

9.  The Effect of the EGFR - Targeting Compound 3-[(4-Phenylpyrimidin-2-yl) Amino] Benzene-1-Sulfonamide (13f) against Cholangiocarcinoma Cell Lines.

Authors:  Papavee Samatiwat; Lueacha Tabtimmai; Prapasiri Suphakun; Nattanan Jiwacharoenchai; Borvorrnvat Toviwek; Veerapol Kukongviriyapan; M Paul Gleeson; Kiattawee Choowongkomon
Journal:  Asian Pac J Cancer Prev       Date:  2021-02-01

10.  A SEER-based multi-ethnic picture of advanced intrahepatic cholangiocarcinoma in the United States pre- and post-the advent of gemcitabine/cisplatin.

Authors:  Kabir Mody; Samuel O Antwi; David O Hodge; Sikander Ailawadhi; Lewis Roberts; Tanios Bekaii-Saab
Journal:  J Gastrointest Oncol       Date:  2018-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.